Technology

AddToAny

Google+ Facebook Twitter Twitter

UK biomedical catalyst award

Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst programme.

Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias.

centauritherapeutics.com

Related Articles

"HIV vaccine design shows promise"

A novel protein-sugar vaccine candidate has stimulated an immune response against sugars that form a protective shield around HIV.

Four decades of tuberculosis

Professor Douglas Young discusses the last 40 years of tuberculosis research, as he hangs up his lab coat for the final time.

Chemo-boosting Drug

Drugs developed to treat heart and blood vessel problems could be used in combination with chemot

Top